| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 05/26/2006 | WO2006017752A3 Sulfated oligosaccharides |
| 05/26/2006 | WO2006016903A3 1, 2,4-trioxanes and 1, 2, 4-trioxepanes |
| 05/26/2006 | WO2006016237A3 Heterocyclic derivatives as anti-inflammatory agents |
| 05/26/2006 | WO2006015590A3 Novel formulation for l-tryptophane comprising carbidopa/benserazide |
| 05/26/2006 | WO2006014549A3 Synthesis of azo bonded immunoregulatory compounds |
| 05/26/2006 | WO2006012536A3 Methods and compositions for treating lactose intolerance |
| 05/26/2006 | WO2006009874A3 Methods and compositions for treatment of excess nitric oxide or cyanide toxicity |
| 05/26/2006 | WO2006007881A3 New pharmaceutical compositions based on fluorenecarboxyclic acid esters and soluble tnf receptor fusion proteins |
| 05/26/2006 | WO2006005415A3 Use of l-carnitine and glucose for the treatment of cardiovascular diseases |
| 05/26/2006 | WO2006004660A3 Detection of mutations in a gene associated with resistance to viral infection |
| 05/26/2006 | WO2006004636A3 Fused heterocyclic kinase inhibitors |
| 05/26/2006 | WO2006004613A3 Guanylhydrazone salts, compositions, processes of making and methods of using |
| 05/26/2006 | WO2006002361A3 2-methylpropanamides and their use as pharmaceuticals |
| 05/26/2006 | WO2006000922A3 5-aza-7-deazapurine derivatives for treating infections with flaviviridae |
| 05/26/2006 | WO2005123080A3 Nitrogen-containing heterocyclyl substituted imidazoquinolines and imidazonaphthyridines |
| 05/26/2006 | WO2005123077A3 Heteroaryl sulfones and sulfonamides and therapeutic uses thereof |
| 05/26/2006 | WO2005120518A3 Use of atp analogues for treatment of cardiovascular diseases |
| 05/26/2006 | WO2005120435A3 Method for preparing sustained release compositions and the use of said compositions for treating chronic diseases of central nervous system (cns) |
| 05/26/2006 | WO2005118551A3 Thrombopoietin activity modulating compounds and methods |
| 05/26/2006 | WO2005115471A3 Methods and compositions for treatment of nicotine dependence and dementias |
| 05/26/2006 | WO2005113557A8 Method for the catalytic production of hydrocodone and hydromorphone |
| 05/26/2006 | WO2005110438A3 Methods and products related to the intracellular delivery of polysaccharides |
| 05/26/2006 | WO2005108358A3 Pyrrolidine derivatives useful as bace inhibitors |
| 05/26/2006 | WO2005084754A3 Cancer treatment with topoisomerase-ii inhibitor, a bis-dioxypiperazine and radiation |
| 05/26/2006 | WO2005080338A3 New pharmaceutical compositions based on benzilic acid esters and soluble tnf receptor fusion proteins |
| 05/26/2006 | WO2005075022A3 Susceptibility gene for myocardial infraction, stroke, and paod; methods of treatment |
| 05/26/2006 | WO2005070884A3 Heterocyclic compounds useful as growth hormone secretagogues |
| 05/26/2006 | WO2005069880A3 Modulation of line-1 reverse transcriptase |
| 05/26/2006 | WO2005063210A3 Loading of a camptothecin drug into colloidal nanoparticles |
| 05/26/2006 | WO2005055993A3 Pharmaceutical preparation containing gabapentin |
| 05/26/2006 | WO2005046796A3 Combinations of a cholesterol biosynthesis inhibitor and a soluble fiber for the treatment of conditions associated with elevated cholesterol levels |
| 05/26/2006 | WO2005034650A8 Weight-loss supplement |
| 05/26/2006 | WO2005021721A3 Carboxylesterase inhibitors |
| 05/26/2006 | WO2005020880A3 Methods for the treatment of endometriosis |
| 05/26/2006 | WO2005018677A3 Use of combination of an epidermal growth factor receptor kinase inhibitor and cytotoxic agents for treatment and inhibition of cancer |
| 05/26/2006 | WO2005002497A3 BIFUNCTIONAL ANTIBIOTICS FOR TARGETING rRNA AND RESISTANCE-CAUSING ENZYMES |
| 05/26/2006 | WO2004113498A3 Rna interferases and methods of use thereof |
| 05/26/2006 | WO2004084835A3 Treating immunological disorder using agonists of interleukin-21/ interleukin-21 receptor |
| 05/26/2006 | CA2596417A1 Composition for promoting osteogenesis and increasing bone mineral content |
| 05/26/2006 | CA2589001A1 Preventive or therapeutic agent for neuropathic pain |
| 05/26/2006 | CA2588963A1 1-substituted-3-.beta.-d-glucopyranosylated nitrogenous hetero-cyclic compounds and medicines containing the same |
| 05/26/2006 | CA2588959A1 The use of vegetable anthraquinone derivatives and vegetable polysaccharides for treating human immunodeficiency virus (hiv) |
| 05/26/2006 | CA2588832A1 Biphosphonic compounds for preventing or limiting fixing of macromolecules, micro-organisms and biofilm on solid, in particular metal or mineral surfaces |
| 05/26/2006 | CA2588778A1 Immunotherapeutic agent |
| 05/26/2006 | CA2588776A1 Substituted amino carboxylic acids |
| 05/26/2006 | CA2588768A1 Aromatic amide derivatives, medicinal compositions containing the same, medical uses of both |
| 05/26/2006 | CA2588766A1 Heterocycle substituted carboxylic acids |
| 05/26/2006 | CA2588649A1 Methods and compositions related to esculentoside a |
| 05/26/2006 | CA2588513A1 3-phenyl-pyrazole derivatives as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto |
| 05/26/2006 | CA2588423A1 Compositions comprising scyllo-inositol derivatives and methods to treat disorders of protein aggregation |
| 05/26/2006 | CA2588381A1 Radiolabelled quinoline-based ligands for the 5-ht6 receptor functionality |
| 05/26/2006 | CA2588216A1 Stable atorvastatin formulations |
| 05/26/2006 | CA2588166A1 Oxylipins from long chain polyunsaturated fatty acids and methods of making and using the same |
| 05/26/2006 | CA2588093A1 Variants of pigment epithelium derived factor and uses thereof |
| 05/26/2006 | CA2588056A1 2,3,4-substituted cyclopentanones as therapeutic agents |
| 05/26/2006 | CA2588034A1 Pyridonecarboxylic acid derivatives or salts thereof |
| 05/26/2006 | CA2587957A1 Methods for purifying trans-(-)-delta-9-tetrahydrocannabinol and trans-(+)-delta-9-tetrahydrocannabinol |
| 05/26/2006 | CA2587883A1 Use of polymer-lipid conjugates in the prevention and treatment of chronic pulmonary disease, allergic rhinitis and asthma |
| 05/26/2006 | CA2587734A1 Exfoliating skin care product |
| 05/26/2006 | CA2587732A1 Glycogen synthase kinase-3 inhibitors |
| 05/26/2006 | CA2587731A1 Anti-inflammatory extract and agent and method for the production thereof |
| 05/26/2006 | CA2587719A1 Method of screening compound regulating the translation of specific mrna |
| 05/26/2006 | CA2587707A1 Composition containing flavan compound |
| 05/26/2006 | CA2587690A1 Drugs and prodrugs useful for the treatment of energy balance in ruminants |
| 05/26/2006 | CA2587669A1 Novel 2h-chromene derivatives as selective estrogen receptor modulators |
| 05/26/2006 | CA2587658A1 Antibiotic compounds, compositions and medical uses |
| 05/26/2006 | CA2587616A1 Use of ribose-cysteine to treat hypoxia by enhancing delivery of glutathione and atp levels in cells |
| 05/26/2006 | CA2587598A1 Bis(thio-hydrazide amides) for increasing hsp70 expression |
| 05/26/2006 | CA2587566A1 Heterocyclylbiphenyl derivates as protein tyrosine phosphatase inhibitors |
| 05/26/2006 | CA2587558A1 Methods of treating erythropoietin-resistance |
| 05/26/2006 | CA2587545A1 Novel compounds that modulate ppar.gamma. type receptors, and use thereof in cosmetic or pharmaceutical compositions |
| 05/26/2006 | CA2587533A1 Amide derivatives, their manufacture and use as pharmaceutical agents |
| 05/26/2006 | CA2587511A1 Substituted [(phenylethanoyl)amino] benzamides and the use thereof in the treatment of inflammatory and cardio-vascular diseases |
| 05/26/2006 | CA2587499A1 Methods of using pde v inhibitors for the treatment of congestive heart failure |
| 05/26/2006 | CA2587495A1 Control of parasites in animals by the use of parasiticidal 2-phenyl-3-(1h-pyrrol-2-yl) acrylonitrile derivatives |
| 05/26/2006 | CA2587427A1 Kinase inhibitors |
| 05/26/2006 | CA2587407A1 A method of modulating b cell functioning |
| 05/26/2006 | CA2587406A1 Methods and compositions for treating pain |
| 05/26/2006 | CA2587391A1 Compositions useful to treat ocular neovascular diseases and macular degeneration |
| 05/26/2006 | CA2587153A1 Inhibitors of 11-.beta. hydroxyl steroid dehydrogenase type 1 and methods of using the same |
| 05/26/2006 | CA2587083A1 Macrocyclic tertiary amine beta-secretase inhibitors for the treatment of alzheimer's disease |
| 05/26/2006 | CA2586612A1 Triazole compounds that modulate hsp90 activity |
| 05/26/2006 | CA2586363A1 Protein tyrosine phosphatase inhibitors and methods of use thereof |
| 05/26/2006 | CA2586358A1 Use of tetrahydrocannabivarin (thcv) as neutral antagonist of the cb1 cannabinoid receptors |
| 05/26/2006 | CA2586231A1 Method for treating hiv infection through co-administration of tipranavir and uk-427, 857 |
| 05/26/2006 | CA2585581A1 Enhancing treatment of hif-1 mediated disorders with adenosine a3 receptor agonists |
| 05/26/2006 | CA2585576A1 Method for treating hiv infection through co-administration of tipranavir and darunavir |
| 05/26/2006 | CA2585502A1 Adhesion preventive and method of preventing adhesion |
| 05/26/2006 | CA2585363A1 Taste-masked multiparticulate pharmaceutical compositions comprising a drug-containing core particle and a solvent-coacervated membrane |
| 05/26/2006 | CA2585359A1 Gaba-steroid antagonists and their use for the treatment of cns disorders |
| 05/26/2006 | CA2585316A1 Benzothiazole formulations and use thereof |
| 05/26/2006 | CA2585172A1 Sulfonyl-substituted bicyclic compounds as modulators of ppar |
| 05/26/2006 | CA2584619A1 Amide compound |
| 05/26/2006 | CA2584343A1 Pharmaceutical compositions comprising a camptothecin derivate |
| 05/26/2006 | CA2583409A1 Phospho-indoles as hiv inhibitors |
| 05/26/2006 | CA2583195A1 Method for treating hiv infection through co-administration of tipranavir and reverset |
| 05/26/2006 | CA2581814A1 Stable tablet formulation of tetrahydrobiopterin |
| 05/26/2006 | CA2581503A1 Pharmaceutical composition comprising a macrolide t-cell immunomodulator and anti-photoaging agent |
| 05/26/2006 | CA2580150A1 Stereoisomerically enriched 3-aminocarbonyl bicycloheptene pyrimidinediamine compounds and their uses |
| 05/26/2006 | CA2574535A1 Diuretic compounds comprising heterocyclic nitric oxide donor groups, compositions and methods of use |